[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100235711":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":17,"centralContacts":24,"locations":32,"responsibleParty":54,"collaborators":56,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":73,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8,11,14],{"label":9,"type":10,"description":10,"interventionNames":10},"Active Surveillance",null,{"label":12,"type":10,"description":13,"interventionNames":10},"Immediate Intervention","May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.",{"label":15,"type":10,"description":16,"interventionNames":10},"Crossover (Delayed Intervention)","Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.",[18,22],{"name":19,"affiliation":20,"role":21},"Mohamad E Allaf, MD, MBA","Johns Hopkins University","PRINCIPAL_INVESTIGATOR",{"name":23,"affiliation":20,"role":21},"Nirmish Singla",[25,29],{"name":23,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","410-502-3692","nsingla2@jhmi.edu",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":31},"Tina Driscoll","twlajni1@jhmi.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Johns Hopkins Hospital","RECRUITING","Baltimore","Maryland","21287","United States",{"type":41,"coordinates":42},"Point",[43,44],-76.61219,39.29038,{"lat":44,"lon":43},[47,51,53],{"name":48,"role":26,"phone":49,"phoneExt":10,"email":50},"Phillip M Pierorazio, MD","4105025984","philpierorazio@jhmi.edu",{"name":48,"role":52,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":19,"role":21,"phone":10,"phoneExt":10,"email":10},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[57],{"name":58,"class":59},"National Comprehensive Cancer Network","NETWORK","100235711",false,"NCT02346435","The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry","DISSRM","Inclusion Criteria:\n\n* Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.\n* Age ≥ 18 and able to read, understand and sign informed consent.\n* Must be willing to adhere to the treatment algorithm and time constraints therein.\n\nExclusion Criteria:\n\n* Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.",true,"ALL","18 Years","100 Years",{"count":71,"type":72},600,"ESTIMATED","5 Years","OBSERVATIONAL","Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \\\u003C=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.",[77],"Kidney Neoplasm",[79,80],"small renal mass","active surveillance","2026-03-04",{"date":83,"type":84},"2026-03-05","ACTUAL",{"date":86,"type":10},"2009-01",{"date":88,"type":72},"2028-01",{"name":5,"class":6},1]